References
- Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev. Anticancer Ther. 11(6), 859–869 (2011).
- Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond.) 7(4), 597–615 (2012).
- Williams A, Datar R, Cote R. Technologies and methods used for the detection, enrichment and characterization of cancer stem cells. Natl Med. J. India. 23(6), 346–350 (2010).
- Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65(13), 5506–5511 (2005).
- Ahmed MA, Aleskandarany MA, Rakha EA et al. A CD44?/CD24? phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res. Treat. 133(13), 979–995 (2012).
- Idowu MO, Kmieciak M, Dumur C et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 43(3), 364–373 (2012).
- Leung EL, Fiscus RR, Tung JW et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 5(11), e14062 (2010).
- Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma--their prognostic significance. Pathol. Int. 62(12), 792–801 (2012).
- Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756–760 (2006).
- Zhao P, Lu Y, Jiang X, Li X Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 102(5), 1107–1111 (2011).
- Tirino V, Camerlingo R, Franco R et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 36(3), 446–453 (2009).
- Douville J, Beaulieu R, Balicki D ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 18(1), 17–25 (2009).
- Dhingra S, Feng W, Brown RE et al. Clinicopathologic significance of putative stem cell markers, CD44 and nestin, in gastric adenocarcinoma. Int. J. Clin. Exp. Pathol. 4(8), 733–741 (2011).
- Zhu J, He J, Liu Y, Simeone DM, Lubman DM Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J. Proteome Res. 11(4), 2272–2281 (2012).
- Kahlert C, Bergmann F, Beck J et al. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer. 11, 275 (2011).
- De Brot M, Rocha RM, Soares FA, Gobbi H Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. Pathology 44(4), 303–312 (2012).
- Mehrazma M, Madjd Z, Kalantari E, Panahi M, Hendi A, Shariftabrizi A Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr. Pathol. 32(3), 192–204 (2012).
- Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J Validation of tissue microarray technology in ovarian carcinoma. Mod. Pathol. 17(7), 790–797 (2004).
- Karlsson C, Bodin L, Piehl-Aulin K, Karlsson MG Tissue microarray validation: a methodologic study with special reference to lung cancer. Cancer Epidemiol. Biomarkers Prev. 18(7), 2014–2021 (2009).
- Hoos A, Urist MJ, Stojadinovic A et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol. 158(4), 1245–1251 (2001).